Weekly Investment Analysts’ Ratings Changes for TScan Therapeutics (TCRX)

Several brokerages have updated their recommendations and price targets on shares of TScan Therapeutics (NASDAQ: TCRX) in the last few weeks:

• 3/7/2025 – TScan Therapeutics had its price target lowered by analysts at Barclays PLC from $14.00 to $3.00. They now have an “overweight” rating on the stock.
• 3/6/2025 – TScan Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
• 3/5/2025 – TScan Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
• 3/5/2025 – TScan Therapeutics had its price target lowered by analysts at Needham & Company LLC from $11.00 to $9.00. They now have a “buy” rating on the stock.

TScan Therapeutics Trading Down 0.6 %

Shares of TCRX opened at $1.79 on Friday. TScan Therapeutics, Inc. has a 1-year low of $1.71 and a 1-year high of $9.69. The company has a 50-day moving average of $2.31 and a 200 day moving average of $3.90. The firm has a market capitalization of $95.53 million, a price-to-earnings ratio of -1.69 and a beta of 0.91. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. On average, research analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TCRX. Brown Brothers Harriman & Co. increased its position in TScan Therapeutics by 88.2% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 143,051 shares of the company’s stock valued at $712,000 after purchasing an additional 67,027 shares during the period. Great Point Partners LLC grew its position in shares of TScan Therapeutics by 8.0% in the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after buying an additional 75,544 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of TScan Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after buying an additional 13,164 shares during the last quarter. Checkpoint Capital L.P. purchased a new position in shares of TScan Therapeutics in the 3rd quarter worth approximately $4,110,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of TScan Therapeutics in the 3rd quarter worth approximately $515,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.